- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06025877
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey (QUIP II)
Quality Improvement PrecivityAD2(TM): A Survey and Clinical Utility Study of the PrecivityAD2 Blood Test in the Evaluation of Cognitive Impairment (QUIP II)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Quality Improvement PrecivityAD2(TM) Clinician Survey and Clinical Utility Study (QUIP II) represents a large-scale initiative for the PrecivityAD2 blood test for use by neurologists, geriatricians, and geropsychiatrists (memory care specialists) who see patients aged 55 years and older with signs or symptoms of MCI or dementia.
C₂N Diagnostics, LLC is a CLIA-certified, CAP-accredited diagnostic testing laboratory based in St. Louis, MO. Its new test, the PrecivityAD2 blood test, measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Leslie M Jacobs, CCRP, PMP
- Phone Number: 314-464-0002
- Email: ljacobs@c2n.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- Recruiting
- UCSF Memory and Aging Center
-
Contact:
- Lawren VandeVrede, MD
- Phone Number: 415-353-4557
- Email: Lawren.vandevrede@ucsf.edu
-
Principal Investigator:
- Lawren VandeVre, MD
-
Santa Monica, California, United States, 90404
- Recruiting
- Pacific Brain Health Center
-
Contact:
- Phone Number: 503-582-7641
- Email: PacificBrainHealthCenter@providence.org
-
Principal Investigator:
- David Merrill, MD
-
-
Illinois
-
Park Ridge, Illinois, United States, 60068
- Recruiting
- Advocate Memory Center
-
Principal Investigator:
- Darren Gitelman, MD
-
Contact:
- Darren Gitelman, MD
- Phone Number: 847-720-6464
- Email: darren.gitelman@aah.org
-
-
Indiana
-
Indianapolis, Indiana, United States, 46256
- Recruiting
- Josephson Wallack Munshower Neurology, P.C.
-
Principal Investigator:
- Kristi George, MD
-
Contact:
- Tajuana Booker, CRC
- Phone Number: 317-537-6061
- Email: Tbooker@jwmneuro.com
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70006
- Recruiting
- Tulane Doctors Neurosurgery Clinic
-
Contact:
- Sereen Askar
- Phone Number: 504-503-7001
- Email: saskar@tulane.edu
-
Principal Investigator:
- Demetrius Maraganore, MD
-
-
Missouri
-
Ozark, Missouri, United States, 65721
- Recruiting
- Sharlin Health and Neurology
-
Contact:
- Shawna Tindall
- Phone Number: 1005 417-485-4330
- Email: shawna@sharlinfxmed.com
-
Principal Investigator:
- Ken Sharlin, MD
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- C2N Diagnostics
-
Contact:
- Leslie M Jacobs
- Phone Number: 314-464-0002
- Email: ljacobs@c2n.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Physician Inclusion Criteria:
- Memory care specialists actively practicing in the United States
- Practice serves individuals with MCI or dementia age > 55 years
- Average patient volume > 25 visits per week (all patients seen across practice)
- Memory care specialist with access to an online electronic survey
Physician Exclusion Criteria:
1) Clinicians who practice in New York
Participant Inclusion Criteria:
- Individual with MCI or dementia
- Age >= 55 years
Participant Exclusion Criteria
- Individual requiring test related blood draw within the state of New York
- Participation does not seem to be in the best interest of the individual, per the ordering clinician
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort A
One time clinician survey post-test following the receipt of the PrecivityAD2 blood test result
|
The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
Other Names:
|
Cohort B
Pre-test as well as post-test and close-out survey following the receipt of the PrecivityAD2 blood test result
|
The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in planned clinical management (Cohort A and B)
Time Frame: Day 20
|
The association of the test result on medical decision making
|
Day 20
|
Change in planned clinical management (Cohort B)
Time Frame: Day 0 vs Day 20
|
Evaluate the planned versus subsequent planned change in clinical management as a result of receiving the test result
|
Day 0 vs Day 20
|
Difference between the actual age and symptomatology versus intended use criteria (Cohort A and B)
Time Frame: Day 90
|
Evaluate the intended use criteria
|
Day 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship between the test result and actual clinical management (Cohort B)
Time Frame: Day 90
|
Association of the test result on subsequent conducted changes in clinical management and test results when evaluating individuals with MCI or dementia in an ambulatory setting
|
Day 90
|
Change in planned clinical management compared to conducted clinical management (Cohort B only)
Time Frame: Day 20 vs Day 90
|
The evaluation of planned versus conducted change in management as a result of receiving the test result
|
Day 20 vs Day 90
|
Change in probability of AD (Cohort A and B)
Time Frame: Day 0 vs Day 20
|
Evaluate the probability of an AD Dx pre and post receipt of the test result
|
Day 0 vs Day 20
|
Change in anti-AD medication use (Cohort A and B)
Time Frame: Day 0 vs Day 20
|
Evaluate anti-AD medication use pre- and post-receipt of the test result
|
Day 0 vs Day 20
|
Change in diagnosis (Cohort B)
Time Frame: Day 0 vs Day 90
|
Evaluate any changes in diagnoses as a result of receiving the AD test result
|
Day 0 vs Day 90
|
Relationship between the test result and planned testing (Cohort B)
Time Frame: Day 0 vs Day 20 vs Day 90
|
Evaluate the association between subsequent test ordering pre and post testing
|
Day 0 vs Day 20 vs Day 90
|
Correlations between the net promoter score and ease of use by APS2 result (Cohort B)
Time Frame: Day 90
|
Focus group questions around net promoter score and ease of use, strengths, and limitations of testing
|
Day 90
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Monane, MD, MBA, AGSF, C₂N Diagnostics, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C2N002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
Stanford UniversityRecruitingMild Cognitive Impairment | Subjective Cognitive ImpairmentUnited States
-
Fondazione Don Carlo Gnocchi OnlusUniversity of Florence; Consorzio di Bioingeneria e Informatica Medica; Gutenberg...CompletedCognitive Dysfunction | Mild Cognitive Impairment | Vascular Cognitive ImpairmentItaly
-
University of California, Los AngelesCompletedMild Cognitive Impairment (MCI) | Age-associated Cognitive ImpairmentUnited States
-
Universidad de ZaragozaNot yet recruitingMild Cognitive Impairment | Randomized Controlled Trial | Subjective Cognitive Impairment
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Region SkaneLund University; Berry LabCompletedMemory Impairment | Cognitive Impairment, MildSweden
-
University of GeorgiaApplied Universal Dynamics, Corp.; Van Robotics, Inc.Active, not recruitingRobot-assisted Cognitive Training for Lonely Older Adults With Mild Cognitive Impairment (MCI) (MCI)Cognitive Change | Aging | Cognitive Impairment, MildUnited States
-
University Health Network, TorontoRecruiting
-
Wake Forest University Health SciencesActive, not recruiting
Clinical Trials on PrecivityAD2(TM) blood test
-
NephroSantNot yet recruitingKidney Transplant Failure and Rejection
-
French National Agency for Research on AIDS and...Completed
-
Pascual Gregori RoigHospital Universitario de la Plana; FUNDACIÓN DAVALOS FLETCHERCompletedHyperbilirubinemia, Neonatal | Anemia Neonatal | Polycythemia SecondarySpain
-
Wingate InstituteTel Aviv UniversityCompleted
-
University Hospital, ToursCompleted
-
University of Southern DenmarkOdense University Hospital; University of Ghana; Odense Patient Data Explorative... and other collaboratorsCompletedAcquired Immunodeficiency Syndrome | Tuberculosis, Pulmonary | Human Immunodeficiency Virus (HIV) | Extrapulmonary TuberculosisGhana
-
Cairo UniversityUnknownClass III Malocclusion | Class II Malocclusion
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Imperial College LondonCompletedHereditary Hemorrhagic Telangiectasia | Pulmonary Arteriovenous MalformationsUnited Kingdom
-
Minovia Therapeutics Ltd.RecruitingMyelodysplastic SyndromesIsrael